Effects of Metformin or an Oral Contraceptive Containing Cyproterone Acetate on Serum C-reactive Protein, Interleukin-6 and Soluble Vascular Cell Adhesion Molecule-1 Concentrations in Women with Polycystic Ovary Syndrome

J. A. Dardzińska; D. Rachoń; M. Kuligowska-Jakubowska; E. Aleksandrowicz-Wrona; A. Płoszyński; B. Wyrzykowski; W. Łysiak-Szydłowska

doi:10.1055/s-0033-1363261

Experimental and Clinical Endocrinology & Diabetes, Inhaltsverzeichnis

Exp Clin Endocrinol Diabetes 2014; 122(2): 118-125
DOI: 10.1055/s-0033-1363261

Article

Effects of Metformin or an Oral Contraceptive Containing Cyproterone Acetate on Serum C-reactive Protein, Interleukin-6 and Soluble Vascular Cell Adhesion Molecule-1 Concentrations in Women with Polycystic Ovary Syndrome

J. A. Dardzińska

¹Department of Clinical Nutrition, Medical University of Gdańsk, Gdańsk, Poland

,

D. Rachoń

²Department of Clinical and Experimental Endocrinology, Institute of Maritime and Tropical Medicine, Medical University of Gdańsk, Gdynia, Poland

,

M. Kuligowska-Jakubowska

²Department of Clinical and Experimental Endocrinology, Institute of Maritime and Tropical Medicine, Medical University of Gdańsk, Gdynia, Poland

,

E. Aleksandrowicz-Wrona

¹Department of Clinical Nutrition, Medical University of Gdańsk, Gdańsk, Poland

,

A. Płoszyński

³Gynaecology and Obstetrics Unit of the Polish Red Cross Maritime Hospital in Gdynia, Gdynia, Poland

,

B. Wyrzykowski

⁴Department of Hypertension and Diabetology, Medical University of Gdańsk, Gdańsk, Poland

,

W. Łysiak-Szydłowska

⁵Faculty of Health Sciences, Powiślański College, Kwidzyn, Poland

› Institutsangaben

Abstract

Objective:

The aim of the present study was to evaluate the effects of commonly used treatment regimens such as metformin (MET) or an oral contraceptive pill (OC) containing ethynyloestradiol and cyproterone acetate (EE-CPA) on surrogate serum CVD risk factors and markers of endothelial dysfunction (CRP, IL-6, sVCAM) in women with PCOS.

Design:

This study was conducted in a crossover design in order to compare the effects of 2 different treatment regimens in the same subject and has been registered under the number NCT01798875 in the ClinicalTrials.gov registry.

Methods:

42 women with PCOS (age range 18–36 years, median BMI 24.9) were randomly assigned to treatment with MET (850 mg bid) or EE-CPA containing OC for 4 months. After 2 months washout period, treatments were crossed over.

Results:

Treatment with and OC increased significantly serum CRP concentrations (from 0.77 mg/l [95% CI: 0.70; 2.18] to 1.70 mg/l [95% CI: 1.65; 3.69], P<0.001). Treatment with MET slightly reduced serum CRP levels, but this difference did not reach statistical significance (P=0.08). 4 months treatment with MET or EE-CPA had no effect on serum IL-6 and sVCAM-1 concentrations (P>0.05).

Conclusions:

Treatment with EE-CPA containing OC for 4 months in women with PCOS significantly raises serum CRP. Since this rise was not accompanied by the increase in serum concentrations of IL-6, which is the most potent and effective stimulant of hepatic CRP production, we can speculate that this effect is caused by the liver first-pass effect of oral oestrogen administration. If this in turn can confer, cardiovascular risk among these women warrants further studies.

Key words

metformin - hormonal contraception - PCOS - cardiovascular risk markers

Volltext

Referenzen

References
1 Fauser BC, Tarlatzis BC, Rebar RW et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3^rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97: 28-38 e25
2 Meyer C, McGrath BP, Teede HJ. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 2007; 30: 471-478
3 Mathur R, Alexander CJ, Yano J et al. Use of metformin in polycystic ovary syndrome. Am J Obstet Gynecol 2008; 199: 596-609
4 Ridker PM, Rifai N, Cook NR et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. Jama 2005; 294: 326-333
5 Gonzalez F. Inflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids 2012; 77: 300-305
6 Rachoń D. Differential diagnosis of hyperandrogenism in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2012; 120: 205-209
7 Morin-Papunen L, Rautio K, Ruokonen A et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 4649-4654
8 Ridker PM, Rifai N, Stampfer MJ et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-1772
9 Castell JV, Gomez-Lechon MJ, David M et al. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990; 12: 1179-1186
10 Costa LO, dos Santos MP, Oliveira M et al. Low-grade chronic inflammation is not accompanied by structural arterial injury in polycystic ovary syndrome. Diabetes Res Clin Pract 2008; 81: 179-183
11 Tarkun I, Arslan BC, Canturk Z et al. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004; 89: 5592-5596
12 Orio Jr F, Palomba S, Cascella T et al. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 2-5
13 Diamanti-Kandarakis E, Paterakis T, Alexandraki K et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006; 21: 1426-1431
14 Vgontzas AN, Trakada G, Bixler EO et al. Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea. Metabolism 2006; 55: 1076-1082
15 Post MS, van der Mooren MJ, Stehouwer CD et al. Effects of transdermal and oral oestrogen replacement therapy on C-reactive protein levels in postmenopausal women: a randomised, placebo-controlled trial. Thromb Haemost 2002; 88: 605-610
16 Silvestri A, Gebara O, Vitale C et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 2003; 107: 3165-3169
17 Luque-Ramirez M, Escobar-Morreale HF. Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations. Horm Metab Res 2010; 42: 815-820
18 Galien R, Garcia T. Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res 1997; 25: 2424-2429
19 Cauci S, Di Santolo M, Culhane JF et al. Effects of third-generation oral contraceptives on high-sensitivity C-reactive protein and homocysteine in young women. Obstet Gynecol 2008; 111: 857-864
20 Baillargeon JP, McClish DK, Essah PA et al. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 2005; 90: 3863-3870
21 Banaszewska B, Pawelczyk L, Spaczynski RZ et al. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab 2007; 92: 456-461
22 Vrbikova J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 2005; 11: 277-291
23 Morin-Papunen L, Vauhkonen I, Koivunen R et al. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2003; 88: 148-156
24 Cagnacci A, Paoletti AM, Renzi A et al. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J Clin Endocrinol Metab 2003; 88: 3621-3625
25 Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod 2007; 22: 317-322
26 Orio F, Manguso F, Di Biase S et al. Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study. Eur J Endocrinol 2007; 157: 69-73
27 Mohlig M, Spranger J, Osterhoff M et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004; 150: 525-532
28 Jakubowska J, Bohdanowicz-Pawlak A, Milewicz A et al. Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. Gynecol Endocrinol 2008; 24: 378-384
29 Moran LJ, Noakes M, Wittert GA et al. Weight loss and vascular inflammatory markers in overweight women with and without polycystic ovary syndrome. Reprod Biomed Online 2012;
30 Gallo MF, Grimes DA, Schulz KF et al. Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet Gynecol 2004; 103: 359-373
31 Ibanez L, De Zegher F. Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception. J Clin Endocrinol Metab 2003; 88: 4720-4724
32 Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best practice & research Clinical endocrinology & metabolism 2013; 27: 13-24
33 Toth PP, Barter PJ, Rosenson RS et al. High-density lipoproteins: A consensus statement from the National Lipid Association. J Clin Lipidol 2013; 7: 484-525
34 Orchard TJ, Temprosa M, Goldberg R et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005; 142: 611-619
35 Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327: 951-953